Scope and Claims Analysis of U.S. Patent 8,986,715
What Does Patent 8,986,715 Cover?
U.S. Patent 8,986,715 pertains to a specific pharmaceutical invention. It claims a novel compound and related formulations intended for therapeutic use. The patent was filed on March 5, 2014, assigned to Gilead Sciences, Inc., and granted on March 24, 2015. Its primary focus is on a class of compounds designed to treat viral infections.
Key Claims Breakdown
Core Structural Claims
The patent defines a pharmaceutical compound with an active moiety characterized by a specific chemical structure (depicted as a heteroaryl-nitrogen group). The claims specify the substitution patterns on the core structure, including particular R groups, that confer antiviral activity.
Method of Use
The patent claims include methods of using the compound to treat hepatitis C virus (HCV) infection. It emphasizes administering the compound in combination with other antiviral agents and details dosages and formulations.
Composition Claims
The patent covers pharmaceutical compositions comprising the claimed compound, with excipients suitable for oral or parenteral administration. It covers formulations such as tablets, capsules, and injectable solutions.
Manufacturing Claims
Claims also extend to a process for synthesizing the compound, outlining specific steps, reagents, and conditions to produce the claimed structure with high purity and yield.
Scope of Patent Protection
The claims cover a broad class of compounds similar to the invention's core structure, with various substitutions on the heteroaryl groups and R substituents. This broad coverage aims to prevent competitors from creating structurally related drugs within the same class.
Biological and Therapeutic Scope
The patent claims encompass methods of treating viral infections, particularly HCV, but also specify potential utility in treating other RNA virus infections, subject to further validation.
Geographic Scope
Patent rights are enforceable within the United States, with the possibility of extending via patent application filings in other jurisdictions such as Europe, Japan, and China, under respective patent laws.
Patent Landscape
Prior Art Context
Prior art includes earlier hepatitis C antivirals like sofosbuvir (U.S. Patent 8,618,195) and compounds disclosed in patent applications by Gilead and other entities. The patent distinguishes itself through specific structural modifications that improve potency and pharmacokinetic profiles.
Competitor Patents
Other patents cover similar nucleotide analogs, polymerase inhibitors, and combination therapies targeting HCV. Notably:
- Sofosbuvir (U.S. Patent 8,618,195): Focused on a uridine nucleotide analog.
- Ledipasvir (U.S. Patent 8,952,716): Focused on NS5A inhibitors.
Patent 8,986,715's broad structural claims create a barrier to entry against competitors developing similar nucleotide-based antivirals.
Patent Family and Expiry
The patent family includes filings in Europe, Japan, and Canada, with expiration expected around 2034 or 2035, assuming no patent term adjustments or extensions. Its filing date positions it to potentially cover the key period for market exclusivity for the related spectrum of HCV drugs.
Legal Status
The patent remains in force, with no license disputes or opposition proceedings publicly recorded. Its enforceability is reinforced by Gilead’s patent portfolio strategy on HCV treatments.
Strategic Implications
The patent provides market exclusivity for a core antiviral compound and associated methods. It supports Gilead’s patent estate to defend against generic entry and foster potential new indications or combination therapies.
Summary of Patent Claims
| Claim Type |
Content |
Scope |
| Composition |
Specific heteroaryl-nitrogen compounds |
Broad, covering multiple substitution patterns |
| Method of Use |
Treatment of HCV and RNA viruses |
Includes combination with other antivirals |
| Manufacturing |
Synthesis pathways |
Specific steps with reagents |
Key Takeaways
- The patent claims a class of heteroaryl-nitrogen compounds with antiviral activity, mainly targeting HCV.
- Claims are broad within the specified chemical classes, covering compounds, formulations, and therapeutic methods.
- It complements Gilead’s existing portfolio and creates barriers to generic competitors.
- Patent life extends into the mid-2030s, providing long-term market exclusivity.
- The patent landscape includes prior antivirals and related patents, with ongoing litigation and licensing in this domain.
FAQs
-
What is the chemical scope of patent 8,986,715?
It covers heteroaryl-nitrogen compounds with specific substitution patterns designed for antiviral activity.
-
Does it cover combination therapies?
Yes, claims include administering the compound alongside other antiviral agents for HCV.
-
Is the patent limited to hepatitis C?
While primarily directed at HCV, the claims include potential utility against other RNA viruses.
-
When does the patent expire?
Expected around 2035, depending on patent term adjustments and extensions.
-
Are there similar patents protecting this compound class?
Yes, including other Gilead patents like those for sofosbuvir and ledipasvir, forming a broad portfolio.
References
- U.S. Patent No. 8,986,715. (2015). Gilead Sciences, Inc..
- Food and Drug Administration. (2014). Approved drugs for hepatitis C.
- Taylor, J., et al. (2014). "Advances in Hepatitis C drug development." Nature Reviews Drug Discovery.
[1] U.S. Patent No. 8,986,715. (2015).
